Loading stock data…
TCRT
$1.99-0.01 (-0.50%)
After Hours$2.12+0.13 (+6.53%)· Last close Jun 9
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alaunos Therapeutics, Inc. in the Healthcare sector is trading at $1.99 with a market capitalization of $5M. The stock is currently near its 52-week low of $1.67, remaining 31.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.99
Potential Downside
0%
Whystock Fair Value$1.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-319.02%
Volume
Today's trading volume
26,339
Recent News
Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers
Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs.
Ziopharm: Q3 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Friday reported a loss of $1.2 million in its third quarter. The Houston-based company said it had a loss of 55 cents per share.
Ziopharm: Q2 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Thursday reported a loss of $1.1 million in its second quarter. On a per-share basis, the Houston-based company said it had a loss of 63 cents.